1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk : A population-based cohort study
2024) In Heart Rhythm(
- Contribution to journal › Article
-
Mark
Impact of direct oral anticoagulants on ROTEM® variables; a sample size-calculated experimental study
(
- Contribution to journal › Article
- 2023
-
Mark
Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
(
- Contribution to journal › Article
- 2022
-
Mark
Dual antithrombotic treatment in chronic coronary syndrome : European Society of Cardiology criteria vs. CHADS-P2A2RC score
(
- Contribution to journal › Article
- 2020
-
Mark
Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and rivaroxaban in atrial fibrillation
(
- Contribution to journal › Article
- 2019
-
Mark
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status : The NAVIGATE ESUS Trial
(
- Contribution to journal › Article
- 2018
-
Mark
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial
(
- Contribution to journal › Article
- 2016
-
Mark
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source : Design of the NAVIGATE ESUS randomized trial
(
- Contribution to journal › Article
- 2012
-
Mark
Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor
(
- Contribution to journal › Article
- 2008
-
Mark
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty : a double-blind, randomised controlled trial
(
- Contribution to journal › Article